Clinical Trials

315 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04236362 2021-01-12

A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer

90 enrolled

Gynecological Cancer

NCT04273815 2020-07-08

A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04203719 2020-06-23

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

140 enrolled

Advanced Head, Neck and Chest Cancer

NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

EndocrineGastrointestinalNET

150 enrolled

Digestive System Neoplasms, Neuroendocrine Tumors

NCT04405505 2020-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

332 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04291248 2020-03-02

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

138 enrolled

Other solid neoplasm

MSI-H or dMMR Advanced Solid Tumors

NCT04234607 2020-01-22

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

738 enrolled

Extensive Small Cell Lung Cancer

NCT03825705 2019-10-31

A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

Gastrointestinal

Carcinoma, Hepatocellular

NCT03897283 2019-10-30

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors

Phase 1 Unknown

22 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03910127 2019-10-30

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

Phase 1 Unknown

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04106024 2019-09-26

Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04073537 2019-08-29

Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer

386 enrolled

Squamous Non-small Cell Lung Cancer

NCT04073550 2019-08-29

Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer

184 enrolled

Small Cell Lung Carcinoma

NCT03983928 2019-08-15

Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer

30 enrolled

Lung Neoplasms

NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

113 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT03527888 2019-05-21

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

40 enrolled

Sarcoma

Bone Neoplasms

NCT03457844 2018-09-11

A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumor G3

NCT02072044 2017-12-29

Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy

Genitourinary

Carcinoma, Renal Cell

NCT02461407 2017-12-29

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

378 enrolled

Gastrointestinal

Stomach Neoplasms

NCT02752516 2017-09-18

A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics

Phase 1 Unknown

16 enrolled

Tumor-Agnostic

Neoplasms

NCT02449343 2017-04-25

Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

233 enrolled

Sarcoma

NCT02029209 2016-12-16

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

110 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02809534 2016-09-07

ALTER0802